Monoclonal antibodies in lymphoid neoplasia: Principles for optimal combined therapy
- 31 October 2000
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 37, 17-26
- https://doi.org/10.1016/s0037-1963(00)90056-8
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patientsAnnals of Oncology, 2000
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic DrugsCancer Biotherapy & Radiopharmaceuticals, 1997
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow SupportNew England Journal of Medicine, 1993
- Induction of Immune Responses in Patients with B-Cell Lymphoma against the Surface-Immunoglobulin Idiotype Expressed by Their TumorsNew England Journal of Medicine, 1992
- The Multichain Interleukin-2 Receptor: A Target for ImmunotherapyAnnals of Internal Medicine, 1992
- REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1HThe Lancet, 1988
- Spontaneous Alteration of Idiotype in a Monoclonal B-Cell LymphomaNew England Journal of Medicine, 1985
- Emergence of Idiotype Variants during Treatment of B-Cell Lymphoma with Anti-Idiotype AntibodiesNew England Journal of Medicine, 1985
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982